The fluoroquinolones: How long will their utility last?

被引:35
作者
Bakken, JS [1 ]
机构
[1] St Lukes Infect Dis Associates, Duluth, MN 55805 USA
关键词
D O I
10.1080/00365540410019039
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Injudicious use of the fluoroquinolones may result in treatment failure, increased patient morbidity, increased health care cost, and possible patient fatality. Fluoroquinolone-resistant bacteria may also adversely impact the microbiological environment in the hospital, the local community and eventually large geographical regions. Fluoroquinolone resistance develops in a stepwise fashion, and current susceptibility testing methods and recommended MIC susceptible breakpoint values for the United States may fail to identify some bacteria that are resistant due to first step mutations at the fluoroquinolone target site gene sequences. C-8 methoxy-fluoroquinolone compounds are more active against resistant bacteria than the older compounds. Fluoroquinolone resistance relates directly to human and veterinary usage and emerging bacterial resistance poses the single greatest threat to the future survival of the fluoroquinolone drugs as an antibiotic class.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 80 条
[1]   Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].
Allen, GP ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614
[2]   Topoisomerase IV catalysis and the mechanism of quinolone action [J].
Anderson, VE ;
Gootz, TD ;
Osheroff, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) :17879-17885
[3]  
BAKKEN J S, 1992, Clinical Microbiology Newsletter, V14, P94, DOI 10.1016/0196-4399(92)90020-A
[4]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[5]   Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].
Bast, DJ ;
Low, DE ;
Duncan, CL ;
Kilburn, L ;
Mandell, LA ;
Davidson, RJ ;
de Azavedo, JCS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054
[6]  
BERGAN T, 1998, PHARMACOKINETICS FLU
[7]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[8]  
Blondeau JM, 1999, CLIN THER, V21, P3
[9]   RAPID DEVELOPMENT OF CIPROFLOXACIN RESISTANCE IN METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
BLUMBERG, HM ;
RIMLAND, D ;
CARROLL, DJ ;
TERRY, P ;
WACHSMUTH, IK .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1279-1285
[10]   CEFTAZIDIME RESISTANCE AMONG SELECTED NOSOCOMIAL GRAM-NEGATIVE BACILLI IN THE UNITED-STATES [J].
BURWEN, DR ;
BANERJEE, SN ;
GAYNES, RP .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (06) :1622-1625